Short answer
Wave Life Sciences Ltd. (WVE) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q2 2026 financial results announced for quarter ended June 30, 2026.
Wave Life Sciences Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full earnings details furnished in Exhibit 99.1 for investor review
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation furnished July 30, 2026, providing investors with current business and pipeline information
- Exhibit 99.2 contains the presentation and should be reviewed for substantive operational or clinical updates
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 liability standards
Item EX-99.1 · Exhibit EX-99.2
- Q2 2026 results: revenue $2.3M, R&D $51.3M, net loss $69.4M versus $50.5M loss
- Cash, equivalents, and marketable securities $490.6M, supporting operations into 3Q 2028
- WVE-007 Phase 2a obesity dosing underway; Phase 2 incretin-combination and maintenance trials targeted for 2H 2026
- FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006
- WVE-008 CTA submission for PNPLA3 liver disease remains targeted for 2H 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Wave Life Sciences Ltd. 8-K filings
Get the next WVE 8-K as it lands
Follow WVE for push alerts, or ask the research agent what this filing means.